

Surgical removal of an embolized amplatzer device from left ventricle

A Sadeghpour Tabaei,¹ AR Rostami,² R Ghafari,²; AH Sadeghpour Tabaei,²

1. Cardiovascular Surgeon; 2. Resident of Cardiovascular Surgery, Shahid Rajaee Heart Hospital, Tehran, Iran

Coronary artery fistula is an uncommon but hemodynamically significant anomaly of the coronary arteries, occurring as an incidental finding in 0.1% to 0.2% of coronary angiograms. Although half of the patients with a coronary artery fistula remain asymptomatic, the other half develops CHF, infective endocarditis, myocardial ischemia, or rupture of an aneurysm. This report is illustrative of the right coronary artery fistula to the right pulmonary artery in a 57-year-old male. The definitive diagnosis was made during transesophageal echocardiography and confirmed at operation.

Key words: Atrial septal defect(ASD), amplatzer septal occluder (ASO), device embolization

Introduction

Atrial septal defect (ASD) is the prevalent congenital heart disease (3.78 per 10000 live birth).¹ Surgical treatment is safe and effective but the complications relate to thoracotomy, bleeding, arrhythmia, post pericardectomy syndrome, and residual defects¹. There have been some creative efforts by interventional cardiologists in closing ASD using various devices. ASD closure device was first described by Ring et al. in 1976. The devices used for closure are composed of cardioseal, amplatzer septal occluder (ASO), and the angelwings². The amplatzer septal occluder (ASO) is a device approved by FDA for transcatheter closure of secundum atrial septal defects and fenestrations post Fontan operation^{3,4}.

The ASO is a self-expandable, double disc device made from a Nitinol wire mesh. Nitinol is a metal alloy used in many medical appliances. The two discs are linked together by a short connecting waist corresponding to the size of ASD. In order to increase its closing ability, the discs and the waist are filled with polyester fabric³.

Case report

A 12 year-old boy with symptoms of palpitation and fatigue underwent transthoracic echocardiography, which showed a 20 mm diameter secundum ASD, and EF=77%. The patient was therefore seemed to be a good candidate for ASD closure using ASO. After positioning and releasing, the device was embolized to LA and subsequently to LV. Efforts for percutaneous extraction of the device were failed, and the patient was transferred to OR in cardiogenic shock.

Correspondence:

Ali Sadeghpour-Tabaei, MD, Cardiovascular Surgery Department, Rajaee Heart Center, Valiasr Ave, Park Mellat, Tehran, 1996911151, Iran.
Tel: #98-9121157922; Telfax: #98-21-23922143;
E-mail: alisadeghpour@yahoo.com

A midsternotomy incision was made, mediastinal cavity opened and CPB established using 2 venous cannulae and caval tapes. We made an incision in RA, and approached LA and then LV through ASD. The occluding device was then removed, ASD closed primarily and CPB was discontinued easily and without any difficulties. Postoperative echocardiography showed no residual ASD and after an uneventful and normal post operation period, the patient was discharged from hospital.

Discussion

Surgical ASD closure has been performed since 1948 with good results and low mortality and morbidity. The operation needs a sternotomy or less commonly thoracotomy incision, CPB and 3-7 days of hospital admission.⁵ During past few years, different devices for percutaneous closure of ASD have been used for more than 2700 cases worldwide. Amplatzer has been used since 1995 and compared to other competitive devices, and it has passed tests of superiority and applicability. The superiorities of Amplatzer are its simple use and possibility of changing its position. This is due to composition of nitinol (memory wire) and excellent design, which could retract into the catheter and removed if it was not properly placed in the heart. It is available in 40 mm size³. Most ASD secundums can be closed by Amplatzer. Common criteria for a patient being suitable for closure by Amplatzer included a defect with less than or equal to 34 mm, a 4 mm rim of septal tissue surrounding the defect and sufficient distances from surrounding valves and structures³. The hazards of ASD are thick profile of device and high amount

of nitinol in device and the potential for nickel toxicity⁶. Complications of percutaneous ASD closure are air embolism, vascular trauma resulting from large sheathes, device embolization, clot embolization through AV valve, occlusion of pulmonary or systemic venous return, perforation of atrial septum, aortic perforation, infective endocarditis, atrial arrhythmia, device malposition necessitating its removal, delayed breakdown of device and residual atrial⁷⁻¹⁰.

According to reports of FDA, the most common complications following Amplatzer insertion are erosion and perforation of heart. There are some reports of this complication occurring many years after insertion⁴. Embolization does not commonly occur but if developed, the reasons were insufficient rim around the defect, early release of device, and mismatch between the size of ASD and Amplatzer which was due to the use of small Amplatzer for a large ASD. Transesophageal echocardiography (TEE) performed during Amplatzer placement seems to be a potential contributor to preventing technical errors and occurrence of complications¹¹⁻¹³. We recommend using TEE for such interventions since this was not included in our study. The reason for embolization in our patients seemed to be due to both insufficient rim, and mismatch between the size of defect and device. Most cases of embolization were localized to RA and RV in decreasing order of frequency. The reason for this propensity was due to lower pressure in RA and RV compared to those in the left chambers. Contrary to previous reports, embolization in our patient was restricted to left side and LV due to technical error^{9, 11-13}. In a study conducted by Berger et al. in one of 61 cases of ASD closure using

Amplatzer, embolization of the Amplatzer device was observed in the left ventricle. The device could be retrieved from the heart, but vascular surgery was required to extract it from the femoral artery⁹. In our patient nonsurgical retrieval was not possible. In another study performed on 236 patients by Fischer et al. with transcatheter closure of ASD, at cardiac catheterisation, devices were not implanted in 18 patients because of overstretched diameter of the ASD, the unstable device, compromised mitral valve, or obstructed upper right pulmonary vein¹⁴. Upon angiographic and haemodynamic assessment, 8 patients with additional systemic or pulmonary vein anomalies, or an Qp: Qs less than 1.5, were excluded from the study⁸. Bialkowski et al. compared closure and complication rates in 91 children with secundum atrial septal defects. Of these, 44 with mean age, 8.1±4.7 years were treated surgically and 47 with mean age, 10.1±4.9 years were treated by percutaneous Amplatzer septal occluder with complications classified as mild, moderate, or severe. The closure rate was similar in both groups with 42/44 children (95.5%) in the surgical versus 46/47 patients in the device groups (97.5%). As for complications, mild forms were observed in 17/44 patients in the surgical group vs 2/47 in the device group, moderate in 11/44 in the surgical vs 1/47 in the device group; and severe in 2/44 in the surgical group vs none in the device group. Blood products were administered to 18 cases in the surgical and to 1 patient in the device group (P < 0.001). Transcatheter closure of secundum atrial septal defects with the Amplatzer device has the advantage of fewer complications, shorter hospitalization, and re-

duced need for blood products. Nonetheless, the surgeon's ability to close any atrial septal defects regardless of its size or location remains an important advantage of surgery. Surgical Complications include pericardial effusion headache, heartblock, rhythm disturbance, pneumonia, atelectasis, bleeding and stroke². In a report by David et al. 186 patients had atrial defects closed by means of Amplatzer device with no major complications. There were 8 (4.3%) minor complications including 4 device embolizations with 2 removed percutaneously and 2 surgically. Also, 4 instances of arrhythmia comprising 3 transient, and 1 persistent complete heart block. The closure rate for 121 patients with 6 months follow-up was 99%¹⁵.

According to the last reports from US, ASD was closed without any important complications in 186 cases. The patients had a low rate of complications consisting of device embolization which in 2 cases it was extracted percutaneously and in 2 patients surgically, arrhythmia in 3 patients including 1 case of permanent complete heart block. Moreover, in 121 cases, the occlusion rate was 99% after 6 months. In most reports, surgical complications after ASD closure were 10-20%. In comparative studies performed by berger et al., no difference was found between prevalence of complications in surgical or ASO closure of ASD. Embolization and percutaneous extraction of ASO, after releasing the device from its position, was reported, though the prevalence and causes of embolization and effective methods for extraction were not described systematically in a company-designated analysis.

The prevalence of embolization of ASO in a wide range of sizes of ASD and device was observed in 21 cases of 3824 device closures (0.55%). Most embolizations were due to underdeveloped rim or undersized devices. Of 21 cases of embolizations, 15 cases were extrated percutaneously using a goose neck snare without any morbidity or mortality and in 6 cases, it was removed surgically. Other possible causes of embolizations were early release of ASO or lack of meticulous assessment¹¹. Kositseth et al. studying 103 patients from April 1998 to November 2002, reported one case of embolization of ASO (ASD or ASO) in LA, Bialkowski et al. reported one case of embolization of ASO in 181 cases of ASO placement². In a large series, embolization of ASO was reported in 1.1% of cases that required surgical removal in 0.2% of cases. Because the prevalence of embolization of ASO in experienced hand was approximately 1 in 200 cases, operators must be familiar with techniques and instruments and be ready for percutaneous extraction of ASO if necessary. In regard to complication of dehiscence after surgical closure managed by amplatzer, both techniques seemed to have complementary role in the treatment of patients. Amplatzer ASD closure in a single procedure had a lower chance of success than surgery. Overall, there were more complications in the surgical group but in most cases they were minor and did not require any changes in management, Hospital stay and time taken to return to normal activities were significantly shorter in the Amplatzer group patients, but median medical costs was similar for both groups, although the cost of surgical closure seemed to be lower in developing countries¹⁷. Postoperative changes in

sizes of the left and right ventricle indices were more favorable in patients after closure of ASD with ASO (ASD or ASO) compared with surgical procedure^{6,10,11,14,16,17,18-20}. We concluded that device embolization is an uncommon complication of Amplatzer ASD closure, that can be managed surgically or by percutaneous extraction methods.

References

- 1 Bialkowski J, Kusa J, Szkutnik M, et al. percutaneous catheter closure of Atrial septal Defect. Short term and midterm results. *Rev Esp Cardiol* 2003;**56**(4):383-8.
- 2 Bialkowski J, Karwot B, Szkutnik M, et al. Closure of atrial septal defects in children surgery versus amplatzer [reg] device implantation. *Tex Heart Inst J* 2004;**31**(3):220-223.
- 3 Levi DS, Moore JW. Embolization and retrieval of the Amplatzer septal occluder. *Catheter Cardiovasc Inter* 2004;**61**(4):543-7.
4. Pratali S, Mecozzi G, Milano A, et al. Prevention of embolization of a displaced Atrial septal occluder. *Tex Heart Inst J* 2003;**30**(1):88-9.
- 5 Thomson JD, Aburawi EH, Watterson KG, et al. Surgical and transcatheter (Amplatzer) closure of atrial septal defects: a prospective comparison of results and cost. *Heart* 2002;**87**:466-469.
- 6 Doll N, Walther T, Falk V, et al. Secundum ASD closure using a right lateral minithoracotomy: Five-Year experience in 122 patients. *Ann Thorac Surg* 2003;**75**:1527-1530.
- 7 Contrafouris CA, Chatzis AC, Giannopoulos NM, et al. Emergency surgical intervention for runaway atrial septal defect closure devices. *J Thorac Cardiovasc Surg* 2006;**132**:1234-1235.
- 8 Vladimir V. Meskishvili A, Konstantinov IE. Surgery for atrial septal defect: from the first experiments to clinical practice. *Ann Thorac Surg* 2003;**76**:322-327.
- 9 Du ZD, Hijazi ZM, Kleinman CS, et al. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: results of a multicenter nonrandomized trial. *J Am Coll Cardiol* 2002; **39**(11):1836-1844.
- 10 Rastegari M, Redinton AN, Sullivan ID. Influence of the introduction of Amplatzer device on the interventional closure of defects within the oval fossa in children. *Cardiol Young* 2001; **11**(5):521-525.
- 11 Bonow RO, Borer JS, Rosing DR, et al. Left ventricular functional reserve in adult patients with atrial septal defect: pre- and postoperative studies. *Circulation* 1981;**63**(6):1315-1322.
- 12 Vida VL, Barnoya J, O'Connell M, et al. Surgical versus percutaneous occlusion of ostium secundum atrial septal defects results and cost-effective considerations in a low-income country. *J Am Coll Cardiol* 2006;**47**(2):326-331.
- 13 Pawelec-Wojtalik M, Wojtalik M, Mrowczynski W, et al. Comparison of cardiac function in children after surgical and Amplatzer occluder closure of secundum atrial septal defects. *Eur J Cardiothoracic Surg* 2006;**29**(1):89-92.
- 14 <http://www.amplatzer.com/us/products/asd.html>.

- 15** Berger F, Vogel M, Alexi-Meskishvili V, et al. Comparison of results and complications of surgical and Amplatzer device closure of atrial septal defects. *J Thorac Cardiovasc Surg.* 1999;**118**(4):674-8.
- 16** Fischer G, Stieh J, Uebing A, et al. Experience with transcatheter closure of secundum atrial septal defects using the Amplatzer septal occluder: a single centre study in 236 consecutive patients. *Heart* 2003;**89**(2):199-204.
- 17** Wax DF. Therapeutic cardiac catheterization in children. <http://www.childsdoc.org/Fall99/catheterization.asp>.
- 18** Chessa M, Carminati M, Butera G, et al. Early and late complications associated with transcatheter occlusion of secundum atrial septal defect. *J Am Coll Cardiol.* 2002;**39**(6):1061-5.
- 19** <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm>.
- 20** Willcoxson FE, Thomson JD, Gibbs JL. Successful treatment of left atrial disk thrombus on an Amplatzer atrial septal defect occluder with abciximab and heparin. *Heart.* 2004;**90**(5):e30.
- 21** Acar P, Aggoun Y, Abdel-Massih T. Images in cardiology: Thrombus after transcatheter closure of ASD with an Amplatzer septal occluder assessed by three dimensional echocardiographic reconstruction. *Heart* 2002;**88**(1):52.

Visit our site

WWW.ICRJ.IR